BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/26/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Chimerix (CMRX) Provides Update On Anticipated SUPPRESS Enrollment 2/26/2015
Portola Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote 2/26/2015
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 2/26/2015
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015
Dipexium Pharmaceuticals (DPRX) Passes 25% Enrollment In Locilex Pivotal Phase 3 Clinical Trials 2/25/2015
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015
Sunovion Pharmaceuticals Inc. Announces Initiation Of Phase 3 Clinical Trial Program For SUN-101/Eflow (Glycopyrrolate) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 2/25/2015
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015
Antares Pharma, Inc. (ATRS) Announces Positive Top-Line Pharmacokinetic Results From The Quickshot Phase 3 Study In Testosterone Deficient Men 2/25/2015
Cytori Therapeutics, Inc. (CYTX) Receives Positive European Opinion On Orphan Drug Status 2/24/2015
Theravance Biopharma Enrolls First Patient In Phase 3 Registrational Study Of Telavancin In Staphylococcus Aureus Bacteremia 2/24/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data from HEAT Study of ThermoDox In Primary Liver Cancer 2/23/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
ADMA Biologics, Inc. Announces Positive Data On Primary And Secondary Endpoints From Its Pivotal Phase III Clinical Trial For RI-002 At The American Academy of Allergy, Asthma and Immunology (AAAAI) Medical Conference 2/23/2015
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015
Eli Lilly (LLY) Release: Baricitinib Superior To Placebo In Reducing Rheumatoid Arthritis Disease Activity In Second Phase 3 Study 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
EXCLUSIVE: Chimerix (CMRX) Says 2015 Will Be "Pivotal" Year, In Talks With Regulators to Use Antiviral After Transplants 2/19/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Nuo Therapeutics Initiates Phase 4 Study Of Aurix Under CMS Coverage With Evidence Development Program 2/19/2015
Eli Lilly (LLY) Provides Update On Evacetrapib Phase 3 Trial 2/19/2015
CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial Cleared To Begin Patient Enrollment In Malaysia, The 20th Country To Join The Trial 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Genzyme (GENZ) Release: ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (Eliglustat) For Treatment-Naïve Patients With Gaucher Disease Type 1 Published In JAMA 2/18/2015
Elite Pharmaceuticals, Inc. (ELI) Provides Guidance On Phase III Study For ELI-200 2/18/2015
PAREXEL International (PRXL) Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network 2/18/2015
Seattle Genetics, Inc. (SGEN) Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial Of ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At High Risk Of Relapse 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Hyperion Therapeutics (HPTX) Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd. 2/17/2015
MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza 2/17/2015
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Results From Phase 3 Clinical Trial In Oral Cavity Cancer Of The Head And Neck Published In Annals Of Surgical Oncology 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
BIOCEO15: Gilead (GILD) COO Says 6-Week Timeline for Hep C Course Unrealistic, Outlines NASH, Cancer Strategies 2/12/2015
Eisai Inc. (ESALF.PK) Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine 2/12/2015
Chimerix, Inc. (CMRX) Presents Update On Preliminary Data From Advise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings 2/12/2015
Genzyme (GENZ) Presents Phase 3 Clinical Trial Extension Results For Cerdelga® (Eliglustat) At Lysosomal Disease Network’s WORLD Symposium 2015 2/12/2015
The Philippines Is The 19th Country To Clear CEL-SCI (CVM) For Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/11/2015
Baxter International, Inc. (BAX) Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A 2/11/2015
Interim Phase 3 Results Positive for Takeda (TKPYY) Blood Cancer Med Ixazomib 2/10/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus 2/10/2015
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
Galena Biopharma  (GALE) Enrolls 700th Patient In Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 2/9/2015
La Jolla Pharmaceutical Company (LJPC) Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 2/9/2015
Provectus Biopharmaceuticals Inc. Met With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study 2/9/2015
Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder 2/9/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015
Second Breakthrough Status Win for Genentech (RHHBY) Immunotherapy Drug 2/6/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Portola Pharmaceuticals, Inc.'s Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End 2/6/2015
Cognoptix CEO Paul Hartung Says Company Is Preparing For A Pivotal Phase 3 Clinical Trial Of SAPPHIRE Eye Scan Being Developed To Aid In The Early Detection Of Alzheimer’s Disease 2/5/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate Abp 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis 2/4/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015
Roche (RHHBY)’s Phase 3 Study Of Gazyva/Gazyvaro Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
Genentech (RHHBY)’s Phase III Study Of Gazyva Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
EXCLUSIVE: Esperion Therapeutics, Inc. (ESPR) CEO Says FDA Lift Means ETC-1002 Will Be in Phase III Trials By End of 2015 2/4/2015
Flexion Therapeutics (FLXN) Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee 2/3/2015
CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study 2/3/2015
Onconova Therapeutics Inc. (ONTX) Announces Clinical Development Plan For Rigosertib In Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure Of Treatment With Hypomethylating Agents (Hmas) 2/3/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) In Non-Small Cell Lung Cancer 2/2/2015
AbbVie (ABBV) Announces Top-Line Results From Phase 3 Study Of All-Oral Treatment For Hepatitis C In Japan 2/2/2015
Evoke Pharma, Inc. Outlines Progress On Clinical Program 2/2/2015
Chimerix, Inc. (CMRX) Focusing Efforts On CMV And Adenovirus Pivotal Trials 2/2/2015
Emmaus Life Sciences Phase 3 Sickle Cell Disease Trial Data Included In 2015 Highlights Of American Society of Hematology Program 2/2/2015
CEL-SCI (CVM) Reports Record Monthly Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/2/2015
Enanta Pharmaceuticals, Inc. Announces 95 Percent SVR12 Rate In Abbvie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients 2/2/2015
Intercept Pharmaceuticals (ICPT) Rockets as Lead NASH Drug Snags Breakthrough Status From the FDA 2/2/2015
Vital Therapies, Inc. (VTI) (VTL) Announces VTI-208 Phase 3 Clinical Trial Reaches Enrollment Target 1/30/2015
Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation From FDA For Obeticholic Acid For Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis 1/30/2015
Radius (RDUS) Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015) 1/29/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/29/2015
Incyte Corporation (INCY) Announces Publication Of Phase 3 RESPONSE Trial In Patients With Polycythemia Vera In New England Journal Of Medicine 1/29/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Progress With RHB-104 Ongoing Phase 3 Program For Crohn's Disease Following FDA Meeting 1/29/2015
Protein Sciences Corporation Release: Clinical Efficacy Study Of Flublok® Quadrivalent Compares Flublok To A Traditional Egg-Based Flu Vaccine 1/29/2015
OSE Pharma Collaboration For Cancer Trial 1/29/2015
Alzheimer's Drug Discovery Foundation Release: New Approach To Delay Alzheimer's Dementia Onset To Be Tested In Phase 3 Clinical Trial 1/28/2015
Avita Medical Announces First Patient Enrollment In US Pivotal Study Of Recell® For The Treatment Of Burns 1/28/2015
Taxus Cardium (CRXM) Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 1/27/2015
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
CEL-SCI (CVM) Receives Regulatory Clearance To Expand Its Phase 3 Head And Neck Cancer Trial Into Romania 1/26/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
Regeneron (REGN) Release: EYLEA® (aflibercept) Injection Recommended For Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Central Or Branch Retinal Vein Occlusion In The European Union 1/23/2015
ALPHAEON Begins Phase 3 Study For Its Neurotoxin, EVOSYAL 1/22/2015
Shire plc Release: Positive Response From European Decentralised Procedure For Elvanse Adult® (lisdexamfetamine dimesylate) In Adults With ADHD 1/22/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials 1/21/2015
Celator Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia 1/20/2015
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Analyses Of Phase 3 MM-398 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
Choroideremia Research Foundation Release: Groundbreaking Gene Therapy Trial Begins In Philadelphia 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene's Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients 1/20/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Marathon Pharmaceuticals, LLC Receives FDA Fast Track Designation For Deflazacort As A Potential Treatment For Duchenne Muscular Dystrophy 1/19/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 1/16/2015
J.P. Morgan: AstraZeneca PLC (AZN) CEO Says He's Not Worried About Pricing Pressure 1/15/2015
Janssen Pharmaceutical Inc. Release: Real-World Data Published In Clinical Cardiology Show Consistent Safety Performance Of Once-Daily XARELTO® 1/14/2015
Frost & Sullivan Releases Drug Launch And Phase 3 Trial Watch List For Top Therapeutic Areas 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
Antares Pharma, Inc. (ATRS) Announces Update To QuickShot® Testosterone Program 1/13/2015
INSYS Therapeutics To Initiate Five Phase 3 Clinical Trials In 2015 1/13/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Breaking: J.P. Morgan: BioMarin (BMRN) Takes Shot at Sarepta (SRPT), Says DMD Drug Has Better Results So Far 1/13/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020 1/13/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
Radius (RDUS) Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 1/12/2015
Portola Pharmaceuticals, Inc. Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote 1/12/2015
Tesaro, Inc. (TSRO) Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015 1/12/2015
The Lancet Oncology Publishes Phase 3 Data Showing Gilotrif® (Afatinib) Extends Overall Survival In Lung Cancer Patients Whose Tumors Have The Most Common EGFR Mutation Compared With Chemotherapy 1/12/2015
Aerie Pharmaceuticals, Inc. (AERI) Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial (“Rocket 1”) Of Rhopressa™ 1/12/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015
GW Pharmaceuticals (GWPH) Falls as Cannabis Drug Fails Key Cancer Pain Study 1/9/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Topline Results From First Phase 3 Trials Evaluating Monthly Dosing Of Alirocumab In Patients With Hypercholesterolemia 1/9/2015
Portola Pharmaceuticals, Inc. Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO® (Rivaroxaban) Met Primary Endpoint With High Statistical Significance 1/9/2015
Ligand Pharmaceuticals Inc. (LGND) Partner Retrophin (RTRX) Receives Orphan Drug Designation For Sparsentan 1/9/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial 1/8/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/8/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)'s Lead Candidate Delafloxacin Yields Positive Top-Line Results In Phase 3 Study In Patients With ABSSSI 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
Versartis, Inc. (VSAR) Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency 1/8/2015
Chimerix, Inc. (CMRX) Provides Update On Brincidofovir Pivotal Phase 3 Advise Trial For The Treatment Of Adenovirus 1/8/2015
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Analyses Of MM-398 Phase 3 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/8/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
ContraVir Pharmaceuticals Granted FDA Meeting To Discuss Proposal For Phase 3 Trial Of FV-100 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Investigator-Sponsored Phase 2 Study Of Mocetinostat In Non-Hodgkin's Lymphoma 1/6/2015
TONIX Pharmaceuticals, Inc. (TNXP) Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia 1/6/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015
Cerus Corporation (CERS) Reports EU Phase 3 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 1/5/2015
CEL-SCI (CVM)’s 2014 Patient Enrollment Increases Eight-Fold Over 2013 In Its Phase 3 Head And Neck Cancer Trial 1/5/2015
Cempra Pharmaceuticals, Inc. (CEMP) Surges as Lead Oral Antibiotic Meets Main Goal in Phase 3 Study 1/5/2015
Can-Fite BioPharma (CFBI) Completes The Design Of The Rheumatoid Arthritis Phase 3 Study Of Its Lead Drug Candidate Cf101 12/30/2014
Intersect ENT Announces Enrollment Of First Patient In Phase 3 Study Of In-Office Treatment For Recurrent Chronic Sinusitis 12/30/2014
Palatin Technologies (PTN) Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Provectus Biopharmaceuticals Inc. To Meet With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study With Aim To Maximize Speed Of Enrollment 12/22/2014
Creative Bioarray Introduces Mini-Centrifuges With Outstanding Performance 12/22/2014
Radius (RDUS) Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014
Receptos (RCPT) Initiates SUNBEAM Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis 12/22/2014
TetraPhase Pharmaceuticals (TTPH) Surges As Antibiotic Succeeds In Late-Stage Trial 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/19/2014
ImmunoGen, Inc. (IMGN) Reports Roche (RHHBY) Has Provided An Update On The MARIANNE Trial 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
Pfizer (PFE) Reports Top-Line Results From A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As A Treatment For Patients With Postherpetic Neuralgia 12/18/2014
TetraPhase Pharmaceuticals (TTPH) Announces Positive Top-Line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 12/18/2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Extab Corporation Announces Positive Data From Phase 3 Clinical Study Of Cytisine As A Smoking Cessation Aid Published In The New England Journal Of Medicine 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective 12/16/2014
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis 12/16/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 12/15/2014
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 12/15/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits 12/15/2014
Novartis AG (NVS) Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Late-Stage Study 12/12/2014
Nektar Therapeutics (CA) (NKTR) Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Alnylam Pharmaceuticals (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-Ttrsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 12/12/2014
Janssen Research & Development Release: Data From The EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented At San Antonio Breast Cancer Symposium 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014